Patient info Open main menu

Strepsils Triple Action Honey and Lemon Flavour 2.4 mg lozenges – Summary of Product Characteristics (SmPC) for healthcare professionals

Last updated: · Text from the MHRA, as of · About this document

Medicine status: General sale (GSL) Details

The Summary of Product Characteristics (SmPC) is written for healthcare professionals. Patients will find plain advice in the patient information leaflet: how to take, side effects, pregnancy and breast-feeding.

Medicine strength:
2.4 mg
Contains active substance:

Summary of Product Characteristics (SmPC) - Strepsils Triple Action Honey and Lemon Flavour 2.4 mg lozenges

1 NAME OF THE MEDICINAL PRODUCT

Strepsils Triple Action Honey & Lemon Flavour 2.4mg Lozenges

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Hexylresorcinol Ph Eur 2.4mg

Also contains the following excipients:

Propylene Glycol (E1520)

Liquid Sucrose

Liquid Glucose (Wheat starch (containing Gluten) and Sulphites – Sulphur Dioxide (E220))

Honey and Lemon Flavour (containing Bergamot oil (containing bergapten), Citral, Citronellol, d-Limonene, Farnesol, Geraniol and Linalool).

For a full list of excipients, see section 6.1

3 PHARMACEUTICAL FORM

Lozenge

4 CLINICAL PARTICULARS

4.1 Therapeutic indications

As an antiseptic, demulcent and local anaesthetic for the relief of sore throat and its associated pain.

4.2 Posology and method of administration

For oral administration

Adults, the elderly and children 6 years and over: One lozenge dissolved slowly in the mouth every three hours or as required.

Do not take more than 12 lozenges in 24 hours.

Not to be given to children under 6 years.

4.3 Contraindications

Hypersensitivity to any of the ingredients.

4.4 Special warnings and precautions for use

The label will convey:

Do not exceed the stated dose.

Keep out of the reach of children.

Not to be given to children under 6 years.

This product is unsuitable hereditary fructose intolerance, glucose-galactose

malabsorption syndrome, or sucrase-isomaltase deficiency.

Important information about some of the ingredients of this medicine:

  • This medicine contains Glucose (1125 mg per lozenge) and Sucrose (1413 mg per lozenge). Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.
  • This medicine contains Sulphites – Sulphur Dioxide present in liquid glucose which may rarely cause severe hypersensitivity reactions and bronchospasm.
  • This medicine contains only very low levels of gluten (from wheat starch). It is regarded as ‘gluten-free’ and is very unlikely to cause problems if you have coeliac disease. One lozenge contains no more than 22.50 micrograms of gluten. If you have wheat allergy (different from coeliac disease) you should not take this medicine.
  • This medicine contains 3.12 mg Propylene glycol in each lozenge.
  • This medicine contains fragrance with Citral, Citronellol, d-Limonene, Farnesol,

    Geraniol and Linalool. Citral, Citronellol, d-Limonene, Farnesol, Geraniol and Linalool may cause allergic reactions.

  • This medicine contains Bergamot oil (present in Lemon and Honey flavour) which may increase sensitivity to UV light (natural and artificial sunlight).

4.5 Interaction with other medicinal products and other forms of interaction

None known.

4.6 Pregnancy and lactation

There is a lack of evidence of safety of the product in human pregnancy, but hexylresorcinol has been used widely in lozenges for many years without apparent ill consequence. However as with all medicines, caution should be exercised during pregnancy and lactation.

4.7 Effects on ability to drive and use machines

No adverse effects known.

4.8 Undesirable effects

System Organ ClassFrequencyAdverse Events
Immune SystemNot knownHypersensitivity1
Disorders

1 Hypersensitivity reactions may include rash, urticaria and angioedema, which may include swelling of the face, neck, throat or tongue that could affect breathing.

Reporting of Suspected Adverse Reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9 Overdose

Hexylresorcinol overdosage may cause minor gastrointestinal irritation. Treatment would be withdrawal of the product and symptomatic measures as appropriate.

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Hexylresorcinol is a local anaesthetic for topical use on the mucous membranes of the mouth and throat. Mild antiseptic activity has also been demonstrated.

The product base has a demulcent action.

5.2 Pharmacokinetic properties

Pharmacokinetic considerations do not arise since the pharmacological action is local to the oropharyngeal cavity.

5.3 Preclinical safety data

There are no pre-clinical data available specific to the product.

6.1 List of Excipients

Liquid Sucrose, Liquid Glucose (containing wheat starch (containing Gluten), and sulphites – Sulphur Dioxide (E220)), Propylene Glycol (E1520), Honey and Lemon Flavour (containing Bergamot oil (containing bergapten), Citral, Citronellol, d-Limonene, Farnesol, Geraniol and Linalool).

6.2 Incompatibilities

Not applicable

6.3 Shelf life

24 months

6.4 Special precautions for storage

Do not store above 25°C. Store in the original packaging. Keep in the outer carton.

6.5 Nature and contents of container

Blister packs of 250 micron PVC coated 90 gsm PVDC with 20 micron hard temper aluminium foil, heat sealed to the PVC/PVDC blister containing 6, 8, 10, 12, 16, 20, 24, 32 or 36 lozenges in a carton.

6.6 Special precautions for disposal

None specific to the product/ pack

7 MARKETING AUTHORISATION HOLDER

Reckitt Benckiser Healthcare (UK) Ltd

Slough

SL1 3UH

8 MARKETING AUTHORISATION NUMBER(S)

PL 00063/0394

9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE

AUTHORISATION

06/04/2010

10 DATE OF REVISION OF THE TEXT

09/03/2021

About this document

Source: MHRA - Medicines and Healthcare products Regulatory Agency (products.mhra.gov.uk) · Marketing authorisation: PL 00063/0394

Last revision stated in the text: 9 March 2021 · MHRA data as of 13 October 2026

Found a mistake? Tell us on the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Facts about Strepsils Triple Action Honey and Lemon Flavour 2.4 mg lozenges

Prescription needed? No, general sale list medicine (GSL) – also sold outside pharmacies
Active substance Hexylresorcinol
Strength 2.4 mg
Pharmaceutical form Lozenge
How is it taken Oromucosal
Excipients Liquid Sucrose, Liquid Glucose (containing wheat starch (containing Gluten), and sulphites – Sulphur Dioxide (E220)), Propylene Glycol (E1520), Honey and Lemon Flavour (containing Bergamot oil (containing bergapten), Citral, Citronellol, d-Limonene, Farnesol, Geraniol and Linalool).
Pack sizes 24 lozenge
Is it available? Listed as available (NHS Dictionary of Medicines and Devices – not a record of current supplies)
Shelf life 24 months
Storage Do not store above 25°C. Store in the original packaging. Keep in the outer carton.
Drug group (ATC)
  1. R Respiratory system drugs
    1. R02 Throat preparations
      1. R02A Throat preparations
        1. R02AA Antiseptic throat preparations
          1. R02AA12 hexylresorcinol
Marketing authorisation PL 00063/0394 (first authorised 6 April 2010)
Marketing authorisation holder Reckitt Benckiser Healthcare (UK) Ltd
Codes GTIN 5011417568996 · BNF 12030300

Sources: the MHRA product information (products.mhra.gov.uk) and the NHS Dictionary of Medicines and Devices (dm+d), release 10.1.0 of 12 October 2026, NHS Business Services Authority. Contains public sector information licensed under the Open Government Licence v3.0.